ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma. 

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

Belantamab Mafodotin (formerly GSK2857916) is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Iopofosine I 131 (CLR 131) is a phospholipid drug conjugate (PDC) that selectively delivers radiation (a cytotoxic radioisotope called iodine-131) directly to malignant cancer cells. The US Food and Drug Administration (FDA) has granted Cellectar an orphan drug designation for Iopofosine I 131 (CLR 131).

Melphalan Flufenamide (Melflufen, PEPAXTO®) is a peptide-drug conjugate (PDC) that uses specific enzymes that are produced in large amounts by myeloma cells. Once the drug enters the cell, it delivers a toxic payload to attack the cancer cell.

Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma. 

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.